drugset / Trial / NCT03090880
Prophylaxis of Venous Thromboembolism in Advanced Lung Cancer (PROVE)
Phase 3
Terminated
59 enrolled
Assistance Publique - Hôpitaux de Paris
Ministry of Health, France · collabNational Cancer Institute, France · collab
RandomizedParallel-groupSingle-blindPrevention
Summary
Prospective randomized open multicenter trial with blinded adjudication of endpoints to assess the efficacy of six-month low-dose LMWH (Low Molecular Weight Heparin) for the prevention of symptomatic or incidental VTE in patients with stage IV lung cancer and elevated D-dimer.
Timeline
- Start
- 2018-09-14
- Primary completion
- 2021-08-18
- Completion
- 2021-08-18
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tinzaparin | Other / unclassified | 4500 iu | Subcutaneous |